GSK forges $12 billion alliance with Hengrui Pharma
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Upgrades 2025 full-year CDMO sales and margin outlook
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Subscribe To Our Newsletter & Stay Updated